文献速递肿瘤 PET/CT

68Ga-FAPI-RGD在多种癌症中成像成纤维细胞激活蛋白与整合素αvβ3的临床评价

Clinical Evaluation of 68Ga-FAPI-RGD for Imaging of Fibroblast Activation Protein and Integrin αvβ3 in Various Cancer Types.
PubMed 文献 · J Nucl Med · 2023-05-04

研究在3名健康志愿者中评估68Ga-FAPI-RGD的有效剂量,并在22例多种类型癌症患者中评估其PET/CT临床可行性,与18F-FDG及68Ga-FAPI-46对比。结果显示该双受体靶向探针耐受良好,原发及转移灶摄取与靶本比显著高于18F-FDG,淋巴结和骨转移检出率提高,且摄取与靶本比高于68Ga-FAPI-46。

要点

  • 68Ga-FAPI-RGD在健康志愿者和患者中耐受良好,无不良事件。
  • 68Ga-FAPI-RGD PET/CT有效剂量为1.01×10⁻² mSv/MBq。
  • 原发灶和转移灶摄取及靶本比显著高于18F-FDG,淋巴结和骨转移检出率提高。

核心结论

  • 68Ga-FAPI-RGD较18F-FDG和68Ga-FAPI PET/CT显示更高的肿瘤摄取和靶本比。
  • 本研究证明68Ga-FAPI-RGD PET/CT用于多种类型癌症成像的安全性和临床可行性。

研究设计与样本

  • 在3名健康志愿者中评估68Ga-FAPI-RGD的有效剂量。
  • 在22例多种类型癌症患者中评估68Ga-FAPI-RGD PET/CT的临床可行性,并与18F-FDG和68Ga-FAPI-46的结果进行比较。

主要发现

  • 68Ga-FAPI-RGD耐受良好,任何健康志愿者或患者均未发生不良事件。
  • 68Ga-FAPI-RGD PET/CT的有效剂量为1.01×10⁻² mSv/MBq。
  • 原发肿瘤SUVmax为18.0 vs 9.1(P<0.001),TBR为15.2 vs 5.5(P<0.001),68Ga-FAPI-RGD高于18F-FDG。
  • 淋巴结转移SUVmax为12.1 vs 6.1(P<0.001),TBR为13.3 vs 4.1(P<0.001),68Ga-FAPI-RGD高于18F-FDG。
  • 淋巴结转移检出率为99% vs 91%,骨转移检出率为100% vs 80%,68Ga-FAPI-RGD高于18F-FDG。

关键数值与推荐

  • 68Ga-FAPI-RGD PET/CT在原发灶和转移灶的放射性摄取及靶本比显著高于18F-FDG PET/CT。
  • 68Ga-FAPI-RGD PET/CT的放射性摄取和靶本比高于68Ga-FAPI-46 PET/CT。
  • 68Ga-FAPI-RGD PET/CT改善了病灶检出率和肿瘤勾画,尤其对于淋巴结转移(99% vs 91%)和骨转移(100% vs 80%)的诊断。

临床怎么用

  • 原文未据此给出推荐。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

Radiolabeled fibroblast activation protein (FAP) inhibitors (FAPIs) and Arg-Gly-Asp (RGD) peptides have been extensively investigated for imaging of FAP- and integrin αvβ3-positive tumors. In this study, a FAPI-RGD heterodimer was radiolabeled with 68Ga and evaluated in patients with cancer. We hypothesized that the heterodimer, recognizing both FAP and integrin αvβ3, would be advantageous because of its dual-receptor-targeting property. Methods: The effective dose of 68Ga-FAPI-RGD was evaluated in 3 healthy volunteers. The clinical feasibility of 68Ga-FAPI-RGD PET/CT was evaluated in 22 patients with various types of cancer, and the results were compared with those of 18F-FDG and 68Ga-FAPI-46. Results: 68Ga-FAPI-RGD was tolerated well, with no adverse events in any of the healthy volunteers or patients. The effective dose from 68Ga-FAPI-RGD PET/CT was 1.01 × 10-2 mSv/MBq. In clinical investigations with different types of cancer, the radiotracer uptake and tumor-to-background ratio (TBR) of primary and metastatic lesions in 68Ga-FAPI-RGD PET/CT were significantly higher than those in 18F-FDG PET/CT (primary tumors: SUVmax, 18.0 vs. 9.1 [P < 0.001], and TBR, 15.2 vs. 5.5 [P < 0.001]; lymph node metastases: SUVmax, 12.1 vs. 6.1 [P < 0.001], and TBR, 13.3 vs. 4.1 [P < 0.001]), resulting in an improved lesion detection rate and tumor delineation, particularly for the diagnosis of lymph node (99% vs. 91%) and bone (100% vs. 80%) metastases. 68Ga-FAPI-RGD PET/CT also yielded a higher radiotracer uptake and TBR than 68Ga-FAPI-46 PET/CT did. Conclusion: 68Ga-FAPI-RGD exhibited improved tumor uptake and TBR compared with 18F-FDG and 68Ga-FAPI PET/CT. This study demonstrated the safety and clinical feasibility of 68Ga-FAPI-RGD PET/CT for imaging of various types of cancer.

来源:J Nucl Med,查看原文。版权归原作者所有。

引用

  1. Zhao L, Wen X, Xu W, et al. Clinical Evaluation of 68Ga-FAPI-RGD for Imaging of Fibroblast Activation Protein and Integrin αvβ3 in Various Cancer Types. J Nucl Med. 2023. PMID: 37142301. doi:10.2967/jnumed.122.265383

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。